Aventis, part of the sanofi-aventis Group, has been received a contract by the US Department of Health and Human Services (HHS) to produce influenza vaccine containing an attenuated version of the H5N1 influenza virus strain. The H5N1 strain is an avian virus strain that recently emerged in Southeast Asia and other countries and continues to circulate. It has the potential to become a human pandemic strain.
Aventis Pasteur, the human vaccines business of Aventis, part of the sanofi-aventis Group, has agreed to produce two million doses of bulk vaccine containing the potential pandemic virus strain. Production and storage will take place at the company's facility in Swiftwater, Pa. The company will be paid nearly $13 million for the vaccine, a company release said.
David J. Williams, chairman and chief executive officer of Aventis Pasteur says, "This new contract with HHS will further increase our experience in pandemic vaccine production. In addition, we continue to pursue additional opportunities for working with governments around the world on related initiatives."
The H5N1 vaccine will be manufactured from a seed virus provided by the National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH). The seed virus is a weakened version of the wild type virus and was extensively tested prior to delivery to Aventis Pasteur.
Earlier this year, Aventis Pasteur entered into an agreement with NIAID to produce 8,000 doses of the H5N1 influenza virus strain for use in clinical trials.
An influenza pandemic is a global epidemic of an especially virulent virus with the potential for severe morbidity and mortality. According to the World Health Organization, the next pandemic is likely to result in 1 to 2.3 million hospitalizations and 280,000 to 650,000 deaths in industrialized nations. Its impact will most likely be even more devastating in developing countries.